Related Experiment Videos
Treatment of neonatal candidiasis with liposomal amphotericin B(L-AMP-LRC-1): phase II study
R N Kotwani1, P V Bodhe, B G Kirodian
1Department of Clinical Pharmacology, Seth G.S. Medical College and K.E.M. Hospital, Parel, Mumbai 400 012, India.
Insights
A new liposomal amphotericin B (L-AMP-LRC-1) shows effectiveness in treating neonatal candidiasis. This low-cost drug offers a promising alternative for infant fungal infections.
Area of Science:
- Mycology
- Neonatal Medicine
- Pharmacology
Background:
- Neonatal candidiasis poses a significant health risk.
- Existing treatments for invasive fungal infections in neonates can be costly and toxic.
- Liposomal amphotericin B formulations offer improved safety profiles.
Purpose of the Study:
- To evaluate the efficacy and safety of a novel liposomal amphotericin B preparation (L-AMP-LRC-1) in neonates with candidiasis.
- To compare the effectiveness of L-AMP-LRC-1 with existing treatments at a lower dosage.
Main Methods:
- An open-label, phase II clinical study was conducted.
- Twenty-three neonates diagnosed with candidiasis received L-AMP-LRC-1 at a dose of 1 mg/kg for 28 days.
- Treatment outcomes were assessed in 14 assessable patients.
Main Results:
- All 14 assessable neonates achieved a complete clinical response to L-AMP-LRC-1 therapy.
- L-AMP-LRC-1 demonstrated efficacy at a lower dose compared to AmBisome, another liposomal amphotericin B formulation.
- The preparation was well-tolerated in the study population.
Conclusions:
- Liposomal amphotericin B preparation (L-AMP-LRC-1) is an effective treatment for neonatal candidiasis.
- L-AMP-LRC-1 presents a potentially cost-effective therapeutic option for treating fungal infections in newborns.
- Further research into L-AMP-LRC-1 for neonatal fungal infections is warranted.
Abstract:
A liposomal amphotericin B preparation (L-AMP-LRC-1) has been developed and tested successfully in adults by us. This preparation was administered to 23 neonates with candidiasis in an open phase II study. All the 14 assessable patients responded completely to the L-AMP-LRC-1 therapy given at 1 mg/kg for 28 days. Compared to AmBisome, another liposomal formulation of amphotericin B, L-AMP-LRC-1 was effective at lower dose in neonatal candidiasis. Thus L-AMP-LRC-1 appears to be an effective and low cost drug for the treatment of candidiasis.